相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genome-wide screening and cohorts validation identifying novel lncRNAs as prognostic biomarkers for clear cell renal cell carcinoma
Chuanjie Zhang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2020)
Significance of PTEN Mutation in Cellular Process, Prognosis, and Drug Selection in Clear Cell Renal Cell Carcinoma
Caibin Fan et al.
FRONTIERS IN ONCOLOGY (2019)
PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2019)
Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?
Aashil A. Batavia et al.
HISTOPATHOLOGY (2019)
mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance
Steffen Rausch et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
HIF-mediated Suppression of DEPTOR Confers Resistance to mTOR Kinase Inhibition in Renal Cancer
Hong Doan et al.
ISCIENCE (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
PTEN in kidney cancer: A review and meta-analysis
Wan-cai Que et al.
CLINICA CHIMICA ACTA (2018)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (vol 23, pg 313, 2018)
Christopher J. Ricketts et al.
CELL REPORTS (2018)
Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma
Anna Gasinska et al.
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA (2018)
An Integrated Score and Nomogram Combining Clinical and Immunohistochemistry Factors to Predict High ISUP Grade Clear Cell Renal Cell Carcinoma
Junlong Wu et al.
FRONTIERS IN ONCOLOGY (2018)
Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma
Weibin Hou et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
James J. Hsieh et al.
EUROPEAN UROLOGY (2017)
The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry
Sung Han Kim et al.
PLOS ONE (2017)
Phosphatase and tensin homolog (PTEN) expression on oncologic outcome in renal cell carcinoma: A systematic review and meta-analysis
Lu Tang et al.
PLOS ONE (2017)
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
David J. Kwiatkowski et al.
CLINICAL CANCER RESEARCH (2016)
A four-gene signature predicts survival in clear-cell renal-cell carcinoma
Jun Dai et al.
ONCOTARGET (2016)
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors
Sherri Z. Millis et al.
JAMA ONCOLOGY (2016)
Over-expression of DNA-PKcs in renal cell carcinoma regulates mTORC2 activation, HIF-2α expression and cell proliferation
Bing Zheng et al.
SCIENTIFIC REPORTS (2016)
A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma
Ian J. Frew et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 10 (2015)
Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer
Tomoya Mizuno et al.
BMC CANCER (2015)
The PI3K/AKT Pathway and Renal Cell Carcinoma
Huifang Guo et al.
JOURNAL OF GENETICS AND GENOMICS (2015)
Low expression of phosphatase and tensin homolog in clear-cell renal cell carcinoma contributes to chemoresistance through activating the Akt/HDM2 signaling pathway
Jun Chen et al.
MOLECULAR MEDICINE REPORTS (2015)
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma
Arindam P. Ghosh et al.
ONCOTARGET (2015)
Validation of Mammalian Target of Rapamycin Biomarker Panel in Patients with Clear Cell Renal Cell Carcinoma
Ahmed Q. Haddad et al.
CANCER (2015)
UBE3C Promotes Growth and Metastasis of Renal Cell Carcinoma via Activating Wnt/β- Catenin Pathway
Ji Ling Wen et al.
PLOS ONE (2015)
Relevance and Therapeutic Possibility of PTEN-Long in Renal Cell Carcinoma
Hui Wang et al.
PLOS ONE (2015)
Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
Siming Li et al.
BMC CANCER (2014)
Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2014)
Prognostic Significance of Biallelic Loss of PTEN in Clear Cell Renal Cell Carcinoma
Hee Jin Lee et al.
JOURNAL OF UROLOGY (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Site-specific activation of AKT protects cells from death induced by glucose deprivation
M. Gao et al.
ONCOGENE (2014)
Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
Alberto Ocana et al.
PLOS ONE (2014)
Variation in genomic landscape of clear cell renal cell carcinoma across Europe
Ghislaine Scelo et al.
NATURE COMMUNICATIONS (2014)
A pan-cancer proteomic perspective on The Cancer Genome Atlas
Rehan Akbani et al.
NATURE COMMUNICATIONS (2014)
A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Brian C. Grabiner et al.
CANCER DISCOVERY (2014)
Renal cell carcinoma
Eric Jonasch et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution
Rosalie Fisher et al.
GENOME BIOLOGY (2014)
Candidate Tumor Suppressor and pVHL Partner Jade-1 Binds and Inhibits AKT in Renal Cell Carcinoma
Liling Zeng et al.
CANCER RESEARCH (2013)
Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3/Snail signaling in renal cell carcinoma
Yu Zhu et al.
CANCER SCIENCE (2013)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
Integrated molecular analysis of clear-cell renal cell carcinoma
Yusuke Sato et al.
NATURE GENETICS (2013)
TCPA: a resource for cancer functional proteomics data
Jun Li et al.
NATURE METHODS (2013)
The Molecular Biology of Renal Cell Carcinoma
Stephen M. Keefe et al.
SEMINARS IN ONCOLOGY (2013)
NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma
Shangwen Liu et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma
Oussama M. Darwish et al.
UROLOGY (2013)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Prognostic Factors in Patients With Advanced Renal Cell Carcinoma
Carolina Muriel Lopez et al.
CLINICAL GENITOURINARY CANCER (2012)
pS6 Expression in Normal Renal Parenchyma, Primary Renal Cell Carcinomas and their Metastases
Martina Hager et al.
PATHOLOGY & ONCOLOGY RESEARCH (2012)
A Functional Variant in the MTOR Promoter Modulates Its Expression and Is Associated with Renal Cell Cancer Risk
Qiang Cao et al.
PLOS ONE (2012)
Inhibition of PTEN Gene Expression by Oncogenic miR-23b-3p in Renal Cancer
Mohd Saif Zaman et al.
PLOS ONE (2012)
Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma
B. Amend et al.
WORLD JOURNAL OF UROLOGY (2012)
Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas
Luciana Schultz et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
The Mammalian Target of Rapamycin Pathway Is Widely Activated Without PTEN Deletion in Renal Cell Carcinoma Metastases
Tamer Abou Youssif et al.
CANCER (2011)
PTEN, pAKT, and pmTOR Expression and Subcellular Distribution in Primary Renal Cell Carcinomas and Their Metastases
Martina Hager et al.
CANCER INVESTIGATION (2011)
mTOR Inhibitors in Advanced Renal Cell Carcinoma
Martin H. Voss et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2011)
Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma
Blanka Kucejova et al.
MOLECULAR CANCER RESEARCH (2011)
Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness
X. He et al.
ONCOGENE (2011)
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
T. Sato et al.
ONCOGENE (2010)
PTEN suppression of YY1 induces HIF-2 activity in von hippel lindau null renal cell carcinoma
Brenda L. Petrella et al.
CANCER BIOLOGY & THERAPY (2009)
TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2
Jeremy Copp et al.
CANCER RESEARCH (2009)
Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays
Meng Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
The PTEN regulator DJ-1 is associated with hTERT expression in clear cell renal cell carcinoma
Raviprakash T. Sitaram et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Increased activated Akt expression in renal cell carcinomas and prognosis
Martina Hager et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma
L. Campbell et al.
BRITISH JOURNAL OF CANCER (2008)
SnapShot: PTEN signaling pathways
Arkaitz Carracedo et al.
CELL (2008)
Tenets of PTEN tumor suppression
Leonardo Salmena et al.
CELL (2008)
Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
Alfredo Toschi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
pVHL: A Multipurpose Adaptor Protein
Ian J. Frew et al.
SCIENCE SIGNALING (2008)
Activation of PI3K is associated with reduced survival in renal cell carcinoma
Axel S. Merseburger et al.
UROLOGIA INTERNATIONALIS (2008)
Hypoxia-inducible factor 1α in clear cell renal cell carcinoma
Tobias Klatte et al.
CLINICAL CANCER RESEARCH (2007)
Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma
Lizhi He et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2007)
Cancer-specific mutations in phosphatidylinositol 3-kinase
Peter K. Vogt et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Prognostic relevance of the mTOR pathway in renal cell carcinoma - Implications for molecular patient selection for targeted therapy
Allan J. Pantuck et al.
CANCER (2007)
Activation of the mTOR signaling pathway in renal clear cell carcinoma
Victoria A. Robb et al.
JOURNAL OF UROLOGY (2007)
Mammalian target of rapamycin inhibitors in renal cell carcinoma: Current status and future applications
Allan J. Pantuck et al.
SEMINARS IN ONCOLOGY (2006)
PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR
Rosa Bernardi et al.
NATURE (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning
SL Cai et al.
JOURNAL OF CELL BIOLOGY (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
Molecularly targeted therapy in renal cell carcinoma
W. Kimryn Rathmell et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2005)
Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: A retrospective nation-wide study of 629 patients
T Gudbjartsson et al.
EUROPEAN UROLOGY (2005)
Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor
S Hara et al.
ANNALS OF ONCOLOGY (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
DA Altomare et al.
ONCOGENE (2004)
The biology and clinical relevance of the PTEN tumor suppressor pathway
I Sansal et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Advances in protein kinase B signalling:: AKTion on multiple fronts
DP Brazil et al.
TRENDS IN BIOCHEMICAL SCIENCES (2004)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma
JC Cheville et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma
A Horiguchi et al.
JOURNAL OF UROLOGY (2003)
Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth
JS Lee et al.
JOURNAL OF SURGICAL ONCOLOGY (2003)
Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin
CC Hudson et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Loss of tumor suppressor protein PTEN during renal carcinogenesis
W Brenner et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Phosphorylation of the PTEN tail regulates protein stability and function
F Vazquez et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
